Ophthalmology Core Facility

总体核心项目摘要 该P30眼科核心设施为NEI资助的俄勒冈州健康和科学提供持续支持 大学（OHSU）和凯西眼科研究所的视力研究人员。四个资源核心是：生物成像和 共聚焦显微镜;基因表达和操作;眼部疾病的遗传模型和生物统计学;以及 蛋白质组学这些共享资源将提供个人无法获得的设备和人员， 研究人员在广泛的威胁视力的疾病，包括白内障，青光眼，黄斑 视网膜变性、糖尿病性视网膜病变、葡萄膜炎、儿童眼病、视觉生理学和视网膜病变的遗传学。 青光眼、黄斑变性、葡萄膜炎和遗传性视网膜疾病。生物成像与共聚焦显微镜 核心将支持共聚焦显微镜研究，使用最先进的仪器进行识别和高分辨率成像。 蛋白质的解析定位。此外，该核心将继续支持小动物成像， 维护Micron IV视网膜成像显微镜，用于啮齿动物眼睛的体内成像。基因表达 &操纵核心将为一系列分子方法提供仪器和技术支持， 确定基因表达和蛋白质水平的变化，并寻找可以 例如RNAi沉默、基因过表达或通过CRISPR/Cas9进行的基因编辑。遗传 眼科疾病模型和生物统计学核心（原分子遗传学和生物统计学）将继续 提供从病人血液样本、唾液和组织中提取DNA的服务， 研究者使用先进的统计技术，以确保在研究设计和 用于数据分析。生物统计服务包括分析复杂的基因表达阵列和RNA-seq 数据集、大型蛋白质组学研究、光学相干断层扫描（OCT）和OCT血管造影研究， 来自生物信息学和临床研究的大型患者人群数据集。两项新服务将提供 (1)来自人、非人灵长类动物、大鼠、小鼠和猪组织的细胞、组织和生物样品的基因分型 和（2）帮助建立来自眼组织的原代细胞培养物，以及来自 眼部疾病患者。提供这些新的服务将使功能基因型-表型研究， 眼科疾病，在当今精准医疗时代的关键增强。蛋白质组学核心将提供 获得先进的高通量技术，用于测量蛋白质丰度和修饰的变化 与疾病有关，决定蛋白质如何折叠和相互作用，以及它们如何调节发育。 所有四个核心是高度互补的，并结合新的计划，旨在鼓励 临床医生和基础科学家之间的沟通，将增加发现，更大的直接利益， 患者

OVERALL CORE PROJECT SUMMARY This P30 Ophthalmology Core Facility provides ongoing support for NEI-funded Oregon Health and Science University (OHSU) and Casey Eye Institute vision researchers. The four resource cores are: Bioimaging & Confocal Microscopy; Gene Expression & Manipulation; Genetic Models of Ocular Disease & Biostatistics; and Proteomics. These shared resources will provide equipment and personnel otherwise not available to individual researchers working in a wide range of vision-threatening diseases, including cataracts, glaucoma, macular degeneration, diabetic retinopathy, uveitis, pediatric eye disease, the physiology of vision and the genetics of glaucoma, macular degeneration, uveitis and inherited retinal diseases. The Bioimaging & Confocal Microscopy core will support confocal microscopy studies using state-of-the-art instrumentation for identification and high- resolution localization of proteins. In addition, this core will continue to support small animal imaging through maintenance of a Micron IV Retinal Imaging Microscope for in vivo imaging of rodent eyes. The Gene Expression & Manipulation core will provide instrumentation and technical support for a range of molecular methods to identify changes in levels of gene expression and proteins, and for methods by which these responses can be manipulated, such as RNAi silencing, gene overexpression or gene editing by CRISPR/Cas9. The Genetic Models of Ocular Disease & Biostatistics core (formerly Molecular Genetics & Biostatistics) will continue to provide DNA isolation services from patient blood samples, saliva and tissue and provide access for NEI investigators to advanced statistical techniques to ensure use of appropriate methods both in study design and for data analysis. Biostatistical services include analysis of complex gene expression arrays and RNA-seq datasets, large proteomics studies, optical coherence tomography (OCT) and OCT angiography studies and large patient population data sets from bioinformatics and clinical research studies. Two new services will provide (1) genotyping of cell, tissue and biological samples from human, non-human primate, rat, mouse and pig tissues and (2) provide assistance in establishing primary cell cultures from ocular tissues, as well as fibroblasts from patients with ocular disease. Offering these new services will enable functional genotype-phenotype studies for ocular disease, a critical enhancement in the current age of precision medicine. The Proteomics core will provide access to advanced, high-throughput techniques for measuring changes in protein abundance and modification with disease, determining how proteins fold and interact with one another, and how they regulate development. All four cores are highly complementary and, in combination with new programs designed to encourage communication between clinicians and basic scientists, will increase discoveries with greater direct benefit to patients.